Project Details
Description
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
| Status | Active |
|---|---|
| Effective start/end date | 1/13/22 → 1/31/27 |
Funding
- BRISTOL-MYERS SQUIBB COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.